Company Update (NYSEMKT:HEB): Hemispherx BioPharma, Inc Meets Ampligen Sales Milestone in the 1st Quarter of 2017
Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced today that it has met a major milestone, the commencement of sales of recently manufactured Ampligen in international programs. Hemispherx has also reinitiated its US-based cost recovery program at the price increase recently approved by the FDA. Hemispherx has initiated an accelerated production plan with both its primary and secondary contract manufacturers in order to meet the anticipated future demand for Ampligen in both international programs as well as cost recovery programs.
“In the last quarter of 2016, we began manufacturing new lots of Ampligen. As I mentioned in our last stockholders call, we anticipated generating sales from our newly manufactured lots of Ampligen in the first quarter of 2017. Mission accomplished! We will continue to aggressively pursue this path while we seek FDA approval of Ampligen in the United States,” said Tom Equels, CEO of Hemispherx.
Shares of Hemispherx are currently trading at $0.491, down $0.009 or 1.76%. HEB has a 1-year high of $2.64 and a 1-year low of $0.39. The stock’s 50-day moving average is $0.55 and its 200-day moving average is $0.86.
Hemispherx Biopharma, Inc. is a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and the experimental immunotherapeutic/antiviral Ampligen. Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Ampligen includes application as a treatment for Chronic Fatigue Syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments.